Patents by Inventor Dalit Strauss-Ayali

Dalit Strauss-Ayali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOMODULATING TREATMENTS OF BODY CAVITIES
    Publication number: 20230218521
    Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
    Type: Application
    Filed: March 8, 2023
    Publication date: July 13, 2023
    Applicant: UROGEN PHARMA LTD.
    Inventors: Gil Hakim, Dalit Strauss-Ayali, Astar Friedman, Marina Konorty
  • IMMUNOMODULATING TREATMENTS OF BODY CAVITIES
    Publication number: 20200397695
    Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 24, 2020
    Applicant: UROGEN PHARMA LTD.
    Inventors: Gil Hakim, Dalit Strauss-Ayali, Astar Friedman, Marina Konorty
  • Immunomodulating treatments of body cavities
    Patent number: 10758482
    Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: September 1, 2020
    Assignee: UROGEN PHARMA LTD.
    Inventors: Gil Hakim, Dalit Strauss-Ayali, Astar Friedman, Marina Konorty
  • IMMUNOMODULATING TREATMENTS OF BODY CAVITIES
    Publication number: 20190201334
    Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 4, 2019
    Applicant: UROGEN PHARMA LTD.
    Inventors: Gil Hakim, Dalit Strauss-Ayali, Astar Friedman, Marina Konorty
  • Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
    Patent number: 9801854
    Abstract: Provided herein are methods for treating cancer of a body cavity, including specifically urinary tract cancer, by way of at least one cell cycle regulator, and at least one anti-cancer drug for local treatment; wherein the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: October 31, 2017
    Assignee: UROGEN PHARMA LTD.
    Inventors: Dalit Strauss-Ayali, Gil Hakim, Marina Konorty, Astar Friedman
  • FGF-18 truncated variants having increased receptor specificity and uses thereof
    Patent number: 9226949
    Abstract: The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: January 5, 2016
    Assignee: HEPACORE LTD.
    Inventors: Avner Yayon, Eran Rom, Roy Sirkis, Dalit Strauss-Ayali
  • FGF-18 Truncated Variants Having Increased Receptor Specificity And Uses Thereof
    Publication number: 20130225493
    Abstract: The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.
    Type: Application
    Filed: March 21, 2013
    Publication date: August 29, 2013
    Inventors: Avner Yayon, Eran Rom, Roy Sirkis, Dalit Strauss-Ayali